Researchers develop breathalyser test for lung cancer detection.
M2 PHARMA-June 20, 2014-Researchers develop breathalyser test for lung cancer detection
(C)2014 M2 COMMUNICATIONS
20 June 2014 - Israeli, US and UK researchers have developed a breathalyser test that is able to accurately diagnose lung cancer and identify its stage of progression.
The test, integrating a NaNose nanotech chip, detects the unique signature of volatile organic compounds (VOCs) in exhaled breath. VOCs are chemicals produced by lung cancer tumours.
Findings from a study, involving 358 patients who were either diagnosed with or at risk for lung cancer, showed that the test accurately distinguished healthy people from patients with early-stage lung cancer in 85% of the time, as well as healthy individuals from those with advanced lung cancer in 82% of the cases. Furthermore, the device accurately differentiated early from advanced lung cancer in 79% of the time.
US firm Alpha Szenszor has licensed the technology and intends to commercially launch it over the next few years.
A new, smaller version of the test, able to be plugged into a computer's USB port, has also been developed.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 20, 2014|
|Previous Article:||Augurex, NRC join forces to develop novel rheumatoid arthritis therapies.|
|Next Article:||uniQure signs contract with Medison Pharma.|